Gaps in evidence for the use of medically authorized cannabis: Ontario and Alberta, Canada.
Anxiety
Cancer
Chronic pain
Cohort study
Depression
Epidemiology
Medical cannabis
Nausea
Spasticity
Journal
Harm reduction journal
ISSN: 1477-7517
Titre abrégé: Harm Reduct J
Pays: England
ID NLM: 101153624
Informations de publication
Date de publication:
08 06 2021
08 06 2021
Historique:
received:
12
04
2021
accepted:
01
06
2021
entrez:
9
6
2021
pubmed:
10
6
2021
medline:
26
11
2021
Statut:
epublish
Résumé
With legal access to medical cannabis in Canada since 2001, there is a need to fully characterize its use at both the individual and population levels. We draw on data from Canada's largest cohort study of medical cannabis to identify the primary reasons for medical cannabis authorization in Canada from 2014 to 2019 in two major provinces: Alberta (AB) and Ontario (ON), and review the extent that evidence supports each indication. Self-reported baseline assessments were collected from adult patients in ON (n = 61,835) and AB (n = 3410) who were authorized medical cannabis. At baseline, sociodemographic, primary medical information, and validated clinical questionnaires were completed by patients as part of an individual assessment. Patients' reasons for seeking medical cannabis were compared to published reviews and guidelines to assess the level of evidence supporting medical cannabis use for each condition. Medical cannabis use in both AB and ON was similar in both demographic and reason for authorization. The most common reasons for medical cannabis authorization were: (1) pain (AB = 77%, ON = 76%) primarily due to chronic musculoskeletal, arthritic, and neuropathic pain, (2) mental health concerns (AB = 32.9%, ON = 38.7%) due to anxiety and depression, and (3) sleep problems (AB = 28%, ON = 25%). More than 50 other conditions were identified as reasons for obtaining authorization. In both AB and ON, the majority of reasons for medical cannabis authorization are not substantiated by clinical evidence to fully support its efficacy for long-term use. Ongoing epidemiological studies on medical cannabis on these treatments are warranted to fully outline its treatment benefits or risks.
Sections du résumé
BACKGROUND
With legal access to medical cannabis in Canada since 2001, there is a need to fully characterize its use at both the individual and population levels. We draw on data from Canada's largest cohort study of medical cannabis to identify the primary reasons for medical cannabis authorization in Canada from 2014 to 2019 in two major provinces: Alberta (AB) and Ontario (ON), and review the extent that evidence supports each indication.
METHODS
Self-reported baseline assessments were collected from adult patients in ON (n = 61,835) and AB (n = 3410) who were authorized medical cannabis. At baseline, sociodemographic, primary medical information, and validated clinical questionnaires were completed by patients as part of an individual assessment. Patients' reasons for seeking medical cannabis were compared to published reviews and guidelines to assess the level of evidence supporting medical cannabis use for each condition.
RESULTS
Medical cannabis use in both AB and ON was similar in both demographic and reason for authorization. The most common reasons for medical cannabis authorization were: (1) pain (AB = 77%, ON = 76%) primarily due to chronic musculoskeletal, arthritic, and neuropathic pain, (2) mental health concerns (AB = 32.9%, ON = 38.7%) due to anxiety and depression, and (3) sleep problems (AB = 28%, ON = 25%). More than 50 other conditions were identified as reasons for obtaining authorization.
CONCLUSION
In both AB and ON, the majority of reasons for medical cannabis authorization are not substantiated by clinical evidence to fully support its efficacy for long-term use. Ongoing epidemiological studies on medical cannabis on these treatments are warranted to fully outline its treatment benefits or risks.
Identifiants
pubmed: 34103058
doi: 10.1186/s12954-021-00509-0
pii: 10.1186/s12954-021-00509-0
pmc: PMC8186125
doi:
Substances chimiques
Medical Marijuana
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
61Subventions
Organisme : CIHR
ID : PS 159668
Pays : Canada
Références
Ann Am Thorac Soc. 2018 Oct;15(10):1146-1158
pubmed: 30049223
J Can Assoc Gastroenterol. 2019 Apr;2(1):37-43
pubmed: 31294362
Perm J. 2019;23:18-041
pubmed: 30624194
Pharmacotherapy. 2018 Jun;38(6):651-662
pubmed: 29637590
J Pain Palliat Care Pharmacother. 2018 Dec;32(4):216-225
pubmed: 31070496
J Affect Disord. 2018 Aug 1;235:293-302
pubmed: 29660645
BMC Public Health. 2021 May 1;21(1):843
pubmed: 33933061
Ann Palliat Med. 2017 Dec;6(Suppl 2):S215-S222
pubmed: 28866904
Complement Ther Med. 2020 Mar;49:102328
pubmed: 32147035
BMJ Support Palliat Care. 2020 Dec;10(4):415-420
pubmed: 31959585
BMC Psychiatry. 2019 Oct 29;19(1):328
pubmed: 31664964
Lancet Public Health. 2018 Jul;3(7):e341-e350
pubmed: 29976328
Medicina (Kaunas). 2019 Aug 23;55(9):
pubmed: 31450833
Clin Pharmacol Ther. 2017 Feb;101(2):230-238
pubmed: 27859024
Depress Anxiety. 2017 Mar;34(3):207-216
pubmed: 28245077
Compr Psychiatry. 2018 Jan;80:89-96
pubmed: 29069624
Am J Addict. 2020 Jan;29(1):9-26
pubmed: 31577377
Schmerz. 2016 Feb;30(1):14-24
pubmed: 26787227
J Anesth. 2020 Feb;34(1):95-103
pubmed: 31535218
Clin Psychopharmacol Neurosci. 2017 Nov 30;15(4):301-312
pubmed: 29073741
J Pain Res. 2016 Sep 30;9:735-744
pubmed: 27757048
Depress Anxiety. 2017 Nov;34(11):1006-1017
pubmed: 28636769
Drug Alcohol Depend. 2019 Feb 1;195:13-15
pubmed: 30557813
JAMA. 2015 Jun 23-30;313(24):2456-73
pubmed: 26103030
CMAJ Open. 2021 Apr 13;9(2):E342-E348
pubmed: 33849983
BMC Med Educ. 2015 Mar 19;15:52
pubmed: 25888752
Eur J Intern Med. 2018 Mar;49:7-11
pubmed: 29325791
J Psychiatr Res. 2019 Apr;111:134-139
pubmed: 30738930
BMC Psychiatry. 2020 Jan 16;20(1):24
pubmed: 31948424
Can J Public Health. 2015 Apr 30;106(5):e328-30
pubmed: 26451996
J Clin Neurophysiol. 2020 Jan;37(1):39-49
pubmed: 31895189
Ann Pharmacother. 2019 Nov;53(11):1081-1086
pubmed: 31129977
Can Fam Physician. 2018 Feb;64(2):111-120
pubmed: 29449241
Can Fam Physician. 2018 Feb;64(2):e78-e94
pubmed: 29449262